ALKAL2 and neuroblastoma: This finding suggests that aberrant regulation of the ALKAL2, ALK, and MYCN troika in neuroblastoma, for example in 2p-gain, may drive ALK signaling activity and therefore could benefit from ALK TKI treatment.